Spinal muscular atrophy genotyping by gene dosage using multiple ligation-dependent probe amplification

Oronzo Scarciolla, Liborio Stuppia, Maria Vittoria De Angelis, Stefania Murru, Chiara Palka, Rossella Giuliani, Marta Pace, Antonio Di Muzio, Isabella Torrente, Annunziata Morella, Paola Grammatico, Manlio Giacanelli, Maria Cristina Rosatelli, Antonino Uncini, Bruno Dallapiccola

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Spinal muscular atrophy (SMA) is an autosomal recessive disease characterized by degeneration of the anterior horn cells of the spinal cord, causing symmetric proximal muscle weakness. SMA is classified in three clinical types, SMA I, SMA II, and SMA III, based on the severity of the symptoms and the age of onset. About 95% of SMA cases are caused by homozygous deletion of the survival motor neuron 1 (SMN1) gene (5q13), or its conversion to SMN2. The molecular diagnosis of this disease is usually carried out by a polymerase chain reaction-restriction fragment length polymorphism approach able to evidence the absence of both SMN1 copies. However, this approach is not able to identify heterozygous healthy carriers, which show a very high frequency in general population (1:50). We used the multiple ligation-dependent probe amplification (MLPA) approach for the molecular diagnosis of SMA in 19 affected patient and in 57 individuals at risk to become healthy carriers. This analysis detected the absence of the homozygous SMN1 in all the investigated cases, and allowed to discriminate between SMN1 deletion and conversion to SMN2 on the basis of the size showed by the peaks specific for the different genes mapped within the SMA critical region. Moreover, MLPA analysis evidenced a condition of the absence of the heterozygous SMN1 in 33 out of the 57 relatives of the affected patients, demonstrating the usefulness of this approach in the identification of healthy carriers. Thus, the MLPA technique represents an easy, low cost, and high throughput system in the molecular diagnosis of SMA, both in affected patients and in healthy carriers.

Original languageEnglish
Pages (from-to)269-276
Number of pages8
JournalNeurogenetics
Volume7
Issue number4
DOIs
Publication statusPublished - Nov 2006

Fingerprint

Spinal Muscular Atrophy
Gene Dosage
Ligation
Motor Neurons
Spinal Muscular Atrophies of Childhood
Anterior Horn Cells
Muscle Weakness
Age of Onset
Restriction Fragment Length Polymorphisms
Genes
Spinal Cord
Costs and Cost Analysis
Polymerase Chain Reaction

Keywords

  • MLPA
  • SMN1
  • SMN2
  • Spinal muscular atrophy (SMA)

ASJC Scopus subject areas

  • Genetics(clinical)
  • Neuroscience(all)

Cite this

Spinal muscular atrophy genotyping by gene dosage using multiple ligation-dependent probe amplification. / Scarciolla, Oronzo; Stuppia, Liborio; De Angelis, Maria Vittoria; Murru, Stefania; Palka, Chiara; Giuliani, Rossella; Pace, Marta; Di Muzio, Antonio; Torrente, Isabella; Morella, Annunziata; Grammatico, Paola; Giacanelli, Manlio; Rosatelli, Maria Cristina; Uncini, Antonino; Dallapiccola, Bruno.

In: Neurogenetics, Vol. 7, No. 4, 11.2006, p. 269-276.

Research output: Contribution to journalArticle

Scarciolla, O, Stuppia, L, De Angelis, MV, Murru, S, Palka, C, Giuliani, R, Pace, M, Di Muzio, A, Torrente, I, Morella, A, Grammatico, P, Giacanelli, M, Rosatelli, MC, Uncini, A & Dallapiccola, B 2006, 'Spinal muscular atrophy genotyping by gene dosage using multiple ligation-dependent probe amplification', Neurogenetics, vol. 7, no. 4, pp. 269-276. https://doi.org/10.1007/s10048-006-0051-3
Scarciolla, Oronzo ; Stuppia, Liborio ; De Angelis, Maria Vittoria ; Murru, Stefania ; Palka, Chiara ; Giuliani, Rossella ; Pace, Marta ; Di Muzio, Antonio ; Torrente, Isabella ; Morella, Annunziata ; Grammatico, Paola ; Giacanelli, Manlio ; Rosatelli, Maria Cristina ; Uncini, Antonino ; Dallapiccola, Bruno. / Spinal muscular atrophy genotyping by gene dosage using multiple ligation-dependent probe amplification. In: Neurogenetics. 2006 ; Vol. 7, No. 4. pp. 269-276.
@article{12c16398cd8a4b34a82289237bfb831b,
title = "Spinal muscular atrophy genotyping by gene dosage using multiple ligation-dependent probe amplification",
abstract = "Spinal muscular atrophy (SMA) is an autosomal recessive disease characterized by degeneration of the anterior horn cells of the spinal cord, causing symmetric proximal muscle weakness. SMA is classified in three clinical types, SMA I, SMA II, and SMA III, based on the severity of the symptoms and the age of onset. About 95{\%} of SMA cases are caused by homozygous deletion of the survival motor neuron 1 (SMN1) gene (5q13), or its conversion to SMN2. The molecular diagnosis of this disease is usually carried out by a polymerase chain reaction-restriction fragment length polymorphism approach able to evidence the absence of both SMN1 copies. However, this approach is not able to identify heterozygous healthy carriers, which show a very high frequency in general population (1:50). We used the multiple ligation-dependent probe amplification (MLPA) approach for the molecular diagnosis of SMA in 19 affected patient and in 57 individuals at risk to become healthy carriers. This analysis detected the absence of the homozygous SMN1 in all the investigated cases, and allowed to discriminate between SMN1 deletion and conversion to SMN2 on the basis of the size showed by the peaks specific for the different genes mapped within the SMA critical region. Moreover, MLPA analysis evidenced a condition of the absence of the heterozygous SMN1 in 33 out of the 57 relatives of the affected patients, demonstrating the usefulness of this approach in the identification of healthy carriers. Thus, the MLPA technique represents an easy, low cost, and high throughput system in the molecular diagnosis of SMA, both in affected patients and in healthy carriers.",
keywords = "MLPA, SMN1, SMN2, Spinal muscular atrophy (SMA)",
author = "Oronzo Scarciolla and Liborio Stuppia and {De Angelis}, {Maria Vittoria} and Stefania Murru and Chiara Palka and Rossella Giuliani and Marta Pace and {Di Muzio}, Antonio and Isabella Torrente and Annunziata Morella and Paola Grammatico and Manlio Giacanelli and Rosatelli, {Maria Cristina} and Antonino Uncini and Bruno Dallapiccola",
year = "2006",
month = "11",
doi = "10.1007/s10048-006-0051-3",
language = "English",
volume = "7",
pages = "269--276",
journal = "Neurogenetics",
issn = "1364-6745",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Spinal muscular atrophy genotyping by gene dosage using multiple ligation-dependent probe amplification

AU - Scarciolla, Oronzo

AU - Stuppia, Liborio

AU - De Angelis, Maria Vittoria

AU - Murru, Stefania

AU - Palka, Chiara

AU - Giuliani, Rossella

AU - Pace, Marta

AU - Di Muzio, Antonio

AU - Torrente, Isabella

AU - Morella, Annunziata

AU - Grammatico, Paola

AU - Giacanelli, Manlio

AU - Rosatelli, Maria Cristina

AU - Uncini, Antonino

AU - Dallapiccola, Bruno

PY - 2006/11

Y1 - 2006/11

N2 - Spinal muscular atrophy (SMA) is an autosomal recessive disease characterized by degeneration of the anterior horn cells of the spinal cord, causing symmetric proximal muscle weakness. SMA is classified in three clinical types, SMA I, SMA II, and SMA III, based on the severity of the symptoms and the age of onset. About 95% of SMA cases are caused by homozygous deletion of the survival motor neuron 1 (SMN1) gene (5q13), or its conversion to SMN2. The molecular diagnosis of this disease is usually carried out by a polymerase chain reaction-restriction fragment length polymorphism approach able to evidence the absence of both SMN1 copies. However, this approach is not able to identify heterozygous healthy carriers, which show a very high frequency in general population (1:50). We used the multiple ligation-dependent probe amplification (MLPA) approach for the molecular diagnosis of SMA in 19 affected patient and in 57 individuals at risk to become healthy carriers. This analysis detected the absence of the homozygous SMN1 in all the investigated cases, and allowed to discriminate between SMN1 deletion and conversion to SMN2 on the basis of the size showed by the peaks specific for the different genes mapped within the SMA critical region. Moreover, MLPA analysis evidenced a condition of the absence of the heterozygous SMN1 in 33 out of the 57 relatives of the affected patients, demonstrating the usefulness of this approach in the identification of healthy carriers. Thus, the MLPA technique represents an easy, low cost, and high throughput system in the molecular diagnosis of SMA, both in affected patients and in healthy carriers.

AB - Spinal muscular atrophy (SMA) is an autosomal recessive disease characterized by degeneration of the anterior horn cells of the spinal cord, causing symmetric proximal muscle weakness. SMA is classified in three clinical types, SMA I, SMA II, and SMA III, based on the severity of the symptoms and the age of onset. About 95% of SMA cases are caused by homozygous deletion of the survival motor neuron 1 (SMN1) gene (5q13), or its conversion to SMN2. The molecular diagnosis of this disease is usually carried out by a polymerase chain reaction-restriction fragment length polymorphism approach able to evidence the absence of both SMN1 copies. However, this approach is not able to identify heterozygous healthy carriers, which show a very high frequency in general population (1:50). We used the multiple ligation-dependent probe amplification (MLPA) approach for the molecular diagnosis of SMA in 19 affected patient and in 57 individuals at risk to become healthy carriers. This analysis detected the absence of the homozygous SMN1 in all the investigated cases, and allowed to discriminate between SMN1 deletion and conversion to SMN2 on the basis of the size showed by the peaks specific for the different genes mapped within the SMA critical region. Moreover, MLPA analysis evidenced a condition of the absence of the heterozygous SMN1 in 33 out of the 57 relatives of the affected patients, demonstrating the usefulness of this approach in the identification of healthy carriers. Thus, the MLPA technique represents an easy, low cost, and high throughput system in the molecular diagnosis of SMA, both in affected patients and in healthy carriers.

KW - MLPA

KW - SMN1

KW - SMN2

KW - Spinal muscular atrophy (SMA)

UR - http://www.scopus.com/inward/record.url?scp=33750069739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750069739&partnerID=8YFLogxK

U2 - 10.1007/s10048-006-0051-3

DO - 10.1007/s10048-006-0051-3

M3 - Article

VL - 7

SP - 269

EP - 276

JO - Neurogenetics

JF - Neurogenetics

SN - 1364-6745

IS - 4

ER -